Oppenheimer Asset Management Inc. lowered its stake in Becton, Dickinson and Company (NYSE:BDX) by 3.5% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 31,659 shares of the medical instruments supplier’s stock after selling 1,141 shares during the quarter. Oppenheimer Asset Management Inc.’s holdings in Becton, Dickinson and were worth $6,204,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently added to or reduced their stakes in BDX. Westwood Holdings Group Inc. lifted its holdings in Becton, Dickinson and by 24.2% in the 2nd quarter. Westwood Holdings Group Inc. now owns 1,056,487 shares of the medical instruments supplier’s stock valued at $206,136,000 after purchasing an additional 205,721 shares in the last quarter. Colony Group LLC lifted its holdings in Becton, Dickinson and by 2.1% in the 2nd quarter. Colony Group LLC now owns 11,889 shares of the medical instruments supplier’s stock valued at $2,320,000 after purchasing an additional 239 shares in the last quarter. State Street Corp lifted its holdings in Becton, Dickinson and by 3.5% in the 2nd quarter. State Street Corp now owns 10,270,221 shares of the medical instruments supplier’s stock valued at $2,003,834,000 after purchasing an additional 342,873 shares in the last quarter. Peapack Gladstone Financial Corp lifted its holdings in Becton, Dickinson and by 1.3% in the 2nd quarter. Peapack Gladstone Financial Corp now owns 36,472 shares of the medical instruments supplier’s stock valued at $7,116,000 after purchasing an additional 453 shares in the last quarter. Finally, Janney Montgomery Scott LLC lifted its holdings in Becton, Dickinson and by 35.3% in the 2nd quarter. Janney Montgomery Scott LLC now owns 43,293 shares of the medical instruments supplier’s stock valued at $8,447,000 after purchasing an additional 11,300 shares in the last quarter. 88.46% of the stock is currently owned by hedge funds and other institutional investors.

Becton, Dickinson and Company (NYSE:BDX) opened at $217.81 on Friday. Becton, Dickinson and Company has a fifty-two week low of $161.50 and a fifty-two week high of $229.68. The company has a current ratio of 5.58, a quick ratio of 5.03 and a debt-to-equity ratio of 1.44. The company has a market capitalization of $49,660.00, a price-to-earnings ratio of 23.07, a PEG ratio of 1.71 and a beta of 1.06.

Becton, Dickinson and (NYSE:BDX) last posted its quarterly earnings results on Thursday, November 2nd. The medical instruments supplier reported $2.40 EPS for the quarter, topping the consensus estimate of $2.37 by $0.03. The business had revenue of $3.17 billion for the quarter, compared to analyst estimates of $3.14 billion. Becton, Dickinson and had a return on equity of 20.56% and a net margin of 8.52%. The company’s quarterly revenue was down 2.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.12 EPS. research analysts expect that Becton, Dickinson and Company will post 10.63 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 29th. Investors of record on Friday, December 8th will be given a dividend of $0.75 per share. This represents a $3.00 dividend on an annualized basis and a dividend yield of 1.38%. This is an increase from Becton, Dickinson and’s previous quarterly dividend of $0.73. The ex-dividend date is Thursday, December 7th. Becton, Dickinson and’s dividend payout ratio (DPR) is presently 62.80%.

BDX has been the topic of a number of research reports. Zacks Investment Research upgraded Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $234.00 price objective on the stock in a report on Tuesday, October 31st. Piper Jaffray Companies reiterated a “buy” rating and set a $213.00 price target on shares of Becton, Dickinson and in a report on Tuesday, September 12th. BidaskClub upgraded Becton, Dickinson and from a “hold” rating to a “buy” rating in a report on Monday, August 14th. Cowen reiterated a “buy” rating and set a $230.00 price target on shares of Becton, Dickinson and in a report on Monday, August 14th. Finally, Stifel Nicolaus reiterated a “buy” rating and set a $245.00 price target on shares of Becton, Dickinson and in a report on Friday, November 3rd. Four research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company. Becton, Dickinson and presently has an average rating of “Buy” and a consensus target price of $217.08.

In related news, insider Gary M. Cohen sold 15,512 shares of the firm’s stock in a transaction dated Monday, September 11th. The stock was sold at an average price of $203.77, for a total transaction of $3,160,880.24. Following the completion of the sale, the insider now directly owns 95,781 shares of the company’s stock, valued at approximately $19,517,294.37. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.40% of the stock is currently owned by company insiders.

WARNING: “Becton, Dickinson and Company (BDX) Shares Sold by Oppenheimer Asset Management Inc.” was first reported by Watch List News and is the property of of Watch List News. If you are accessing this news story on another publication, it was illegally copied and republished in violation of U.S. and international trademark & copyright laws. The original version of this news story can be read at https://www.watchlistnews.com/becton-dickinson-and-company-bdx-shares-sold-by-oppenheimer-asset-management-inc/1751429.html.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with Analyst Ratings Network's FREE daily email newsletter.